Bluejay Diagnostics Completes Exercise of All Prefunded Warrants
Event summary
- All prefunded warrants issued in Bluejay Diagnostics' October 2025 private placement have been fully exercised as of February 19, 2026.
- The company now has approximately 972,000 shares of common stock outstanding.
- Cash exercisable warrants for approximately 1.5 million shares remain outstanding with an exercise price of $7.00 or greater per share.
- Recent Schedule 13G filings do not reflect the 1-for-4 reverse stock split that occurred on January 29, 2026.
The big picture
Bluejay Diagnostics' completion of all prefunded warrant exercises marks a significant milestone in its capital structure, providing immediate liquidity. However, the company's ability to commercialize its Symphony System hinges on securing FDA approval, a critical hurdle in the competitive medical diagnostics sector. The recent reverse stock split and outstanding cash exercisable warrants add layers to the company's financial strategy, which will be closely watched by investors.
What we're watching
- Regulatory Approval
- The pace at which Bluejay Diagnostics secures FDA clearance for its Symphony System will determine its market entry timeline.
- Capital Structure
- How the company utilizes the cash from exercised warrants will impact its financial flexibility and strategic initiatives.
- Investor Confidence
- Whether the remaining cash exercisable warrants will be exercised and the impact on share dilution.